Article
Clinical Development of BRAF plus MEK Inhibitor Combinations.
Trends in cancer - 1 Sept 2020
Subbiah Vivek, Baik Christina, Kirkwood John M
Abstract excerpt
Genomic profiling shows that many solid tumors are characterized by specific driver aberrations, and this has expanded the therapeutic options for many patients. The mitogen-activated protein kinase (MAPK) pathway is a key cell signaling pathway involved in regulating cellular growth, proliferation, and survival. Driver mutations in the BRAF gene, a key player in the MAPK pathway, are described in multiple tumor...
Read the complete abstract on PubMedTopics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Cell Differentiation
- Cell Line, Tumor
- Cell Proliferation